Vaxcyte
PCVX
Market cap $14.3B

115.61 USD

-2.32

1.97%

At close Oct 17, 4:00 PM EDT

After hours

115.61

+0.00

0.00%

1 day

-1.97%

5 days

3.59%

1 month

-0.98%

3 months

42.08%

6 months

85.18%

Year to date

83.68%

1 year

148.68%

5 years

342.10%

About: Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.

Employees: 254

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

121% more call options, than puts

Call options by funds: $20.6M | Put options by funds: $9.3M

70% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 23

53% more repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 76

25% more funds holding in top 10

Funds holding in top 10: 12 [Q1] → 15 (+3) [Q2]

14% more capital invested

Capital invested by funds: $8.09B [Q1] → $9.26B (+$1.17B) [Q2]

7% more funds holding

Funds holding: 246 [Q1] → 262 (+16) [Q2]

3.31% more ownership

Funds ownership: 109.32% [Q1] → 112.63% (+3.31%) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$95

18%

downside

Avg. target

$140

21%

upside

High target

$163

41%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Mizuho Salim Syed 44% 1-year accuracy 8 / 18 met price target	41%upside $163	Outperform Maintained	10 Sept 2024
B of A Securities Jason Gerberry 45% 1-year accuracy 9 / 20 met price target	21%upside $140	Buy Maintained	4 Sept 2024
Leerink Partners David Risinger 100% 1-year accuracy 3 / 3 met price target	32%upside $153	Outperform Maintained	3 Sept 2024
Jefferies Roger Song 70% 1-year accuracy 7 / 10 met price target	12%upside $129	Buy Maintained	3 Sept 2024
Needham Joseph Stringer 70% 1-year accuracy 76 / 109 met price target	21%upside $140	Buy Maintained	3 Sept 2024

See Analyst Rankings

Financial journalist opinion

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027

Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025.

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,893,203 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $1.5 billion, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market.

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Vaxcyte Inc.'s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 billion in proceeds.

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Vaxcyte , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high on promising results in a vaccine trial.

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,893,203 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Zacks Investment Research

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.

Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of $1.0 billion of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $150.0 million of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Schaeffers Research

Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower

Vaxcyte Inc (NASDAQ:PCVX) stock is surging today, after the biotechnology company announced positive study results for its drug designed to prevent invasive pneumococcal disease in adults aged 50 or older.

Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower

See News Rankings

Charts implemented using Lightweight Charts™